These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11124594)

  • 1. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study.
    Möcks J
    Nephron; 2000 Dec; 86(4):455-62. PubMed ID: 11124594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
    Dunn CJ; Markham A
    Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
    Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
    Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CREATE trial--building the evidence.
    Eckardt KU;
    Nephrol Dial Transplant; 2001; 16 Suppl 2():16-8. PubMed ID: 11369844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing a fateful alliance: anaemia and cardiovascular outcomes.
    Eckardt KU
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi16-20. PubMed ID: 15958821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
    Levin NW; Fishbane S; Cañedo FV; Zeig S; Nassar GM; Moran JE; Villa G; Beyer U; Oguey D;
    Lancet; 2007 Oct; 370(9596):1415-21. PubMed ID: 17950856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular geometry and cardiovascular mortality based on haemodialysis patient autopsy analyses.
    Mimura I; Nishi H; Mise N; Mori M; Sugimoto T
    Nephrology (Carlton); 2010 Aug; 15(5):549-54. PubMed ID: 20649875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaemia and early phase cardiovascular events on haemodialysis.
    Hayashi T; Joki N; Tanaka Y; Hase H
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():1-6. PubMed ID: 26456311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kohler E; Kes P; Essaian A; Bias P; Buchner A; Elsässer R
    Curr Med Res Opin; 2010 Oct; 26(10):2393-402. PubMed ID: 20812790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The beneficial effects of intervention in early renal disease.
    Portolés J
    Nephrol Dial Transplant; 2001; 16 Suppl 2():12-5. PubMed ID: 11369843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythropoietin on cardiovascular diseases.
    Sunder-Plassmann G; Hörl WH
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S20-5. PubMed ID: 11576916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A need for an individualized approach to end-stage renal disease patients.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 6():17-21. PubMed ID: 12091597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.